SignalEU/UK
Alector: Maintaining 'Hold' ABC Platform Transition And GCase Partnership With Roche
High-priority alert based on source significance and keyword relevance.
Context
What happened: Alector keeps a "Hold" rating after clinical setbacks and the termination of its GSK partnership. It is pivoting to its ABC blood-brain barrier platform, advancing AL137 for Alzheimer's and AL050 for Parkinson's.
Key numbers: Genentech/Roche partnership for AL050 provides $100M upfront and up to $1.17B in milestones, extending cash runway into 2029. AL137 IND filing is expected in Q1 2027, with first patient dosing by April 2027.
Why it matters: The Roche partnership and extended runway support the platform transition, but risks remain if new programs or partnerships falter.
What changed
Alector keeps a "Hold" rating after clinical setbacks and the termination of its GSK partnership. It is pivoting to its ABC blood-brain barrier platform, advancing AL137 for Alzheimer's and AL050 for Parkinson's.
Why it matters
The Roche partnership and extended runway support the platform transition, but risks remain if new programs or partnerships falter.